Scleroderma Market Report 2026

Scleroderma Market Overview

• Scleroderma market size has reached to $2.48 billion in 2025 • Expected to grow to $3.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: The Scleroderma Market's Impact On Toxin Exposure • Market Trend: Key Strategies Of Major Companies In The Scleroderma Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Scleroderma Market?

Scleroderma is a rare, chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of the skin and other tissues. The different treatments cure or halt excessive collagen production, effectively manage symptoms, and reduce the risk of complications associated with scleroderma. The main treatments of scleroderma include medication, surgery, and others. Medication refers to substances, usually in the form of drugs or pharmaceuticals, which are used to prevent, treat, or manage medical conditions, diseases, or symptoms. It is indicated for the treatment of systemic scleroderma and localized scleroderma by hospitals, pharmaceutical stores, and others.

What Is The Scleroderma Market Growth Forecast?

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $3.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to pipeline of novel disease-modifying drugs, adoption of telehealth for chronic disease management, growth in multidisciplinary care models, increased government funding for rare disease research, expansion of patient education and support programs. Major trends in the forecast period include development and approval of novel disease-modifying therapies, increased use of immunosuppressive and antifibrotic agents, growth of patient support and early intervention programs, expansion of systemic scleroderma clinical trials, adoption of multidisciplinary care approaches for chronic management.

Global Scleroderma Market Segmentation

1) By Treatment: Medication, Surgery, Other Treatments 2) By Indication: Systemic Scleroderma, Localized Scleroderma 3) By End User: Hospital, Pharmaceutical Stores, Other End Users Subsegments: 1) By Medication: Immunosuppressants, Antifibrotic Agents, Vasodilators, Corticosteroids, Pain Relievers 2) By Surgery: Lung Transplantation, Other Surgical Interventions 3) By Other Treatments: Physical Therapy, Occupational Therapy, Lifestyle Modifications, Alternative Therapies

What Is The Driver Of The Scleroderma Market?

The exposure to toxins is driving the scleroderma market forward. Exposure to toxins refers to the contact or ingestion of harmful substances that can adversely affect biological systems. The scleroderma market plays a pivotal role in addressing exposure to toxins by advancing research, developing targeted therapies, and enhancing patient care for those affected by scleroderma, a condition with potential environmental and genetic triggers. For instance, in April 2024, according to the data published by the Department for Environment, Food, and Rural Affairs, a UK-based ministerial department, urban background concentrations rose by 3 percent from 2022, reaching 66.8 µg/m³ in 2023, marking the highest value recorded in the time series. Therefore, the exposure of toxins is driving the scleroderma industry.

Key Players In The Global Scleroderma Market

Major companies operating in the scleroderma market are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Kadmon Holdings Inc., FibroGen Inc., Corbus Pharmaceuticals Holdings Inc., CSL Behring, UCB Pharma, Kyowa Kirin, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co. Ltd.

Global Scleroderma Market Trends and Insights

Major companies operating in the scleroderma market are focusing on product launches, such as a clinical trial platform, to advance treatments for scleroderma and identify agents that should progress from Phase IIb to Phase III. A clinical trial platform is a comprehensive infrastructure and framework facilitating the simultaneous evaluation of multiple therapies or interventions in a standardized manner across various clinical trials. For instance, in August 2023, The Scleroderma Research Foundation (SRF), a US-based non-profit organization that funds research into scleroderma, launched CONQUEST, a groundbreaking clinical trial platform. This launch boasts a global reach with enrolment across 130 centers in 22 countries, employing a master protocol for the evaluation of multiple therapies. This groundbreaking initiative is poised to significantly impact the scleroderma market by expediting the development and approval of effective therapies through its collaborative and efficient approach to clinical evaluation.

What Are Latest Mergers And Acquisitions In The Scleroderma Market?

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for approximately $27.8 billion. This acquisition aims to strengthen Amgen's portfolio of first-in-class medicines for rare inflammatory diseases, align with its core strategy of delivering innovative treatments, and leverage its biologics research and manufacturing capabilities to improve health outcomes for patients globally. Horizon Therapeutics plc is an Ireland-based biotechnology company involved in the treatment of scleroderma through Fipaxalparant.

Regional Outlook

North America was the largest region in the scleroderma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Scleroderma Market?

The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Scleroderma Market Report 2026?

The scleroderma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.